TaiGen, YiChang HEC create JV in the Greater China region
Executive Summary
TaiGen Biotechnology Co. Ltd. and YiChang HEC ChangJiang Pharmaceutical Co. Ltd. have created a Chinese joint venture to develop, manufacture, and commercialize direct-acting antiviral agents (DAAs) for treating chronic hepatitis C virus (HCV) in mainland China, Taiwan, Hong Kong, and Macau.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Joint Venture
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice